GlassScriptPhysician profile
Entela Pone
NPI 1508168535
$5,266.95
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,924 · 2020: $1,351 · 2021: $322 · 2022: $341 · 2023: $117 · 2024: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $606.45 | 2019-2024 | Benlysta |
| Pfizer INC. | $548.11 | 2019-2024 | |
| Lilly USA, LLC | $542.94 | 2019-2022 | |
| Amgen INC. | $462.93 | 2019-2021 | |
| Ucb, INC. | $424.34 | 2019-2022 | |
| Abbvie INC. | $357.48 | 2019-2022 | |
| Horizon Therapeutics Plc | $261.62 | 2019-2022 | |
| Janssen Biotech, INC. | $255.09 | 2019-2023 | Simponi, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $251.15 | 2020-2023 | Acthar |
| Genentech USA, INC. | $245.00 | 2019 | |
| Celgene Corporation | $244.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $202.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $158.82 | 2021-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.92 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $102.57 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $100.63 | 2019-2020 | |
| Genzyme Corporation | $81.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2019 | |
| Sobi, INC | $38.88 | 2019 | |
| Antares Pharma, INC. | $23.20 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Entela Pone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.